Breast Cancer and Pregnancy
|
|
- Annabella Waters
- 5 years ago
- Views:
Transcription
1 Breast Cancer and Pregnancy F. Cardoso, MD Director, Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal ESO Breast Cancer Program Coordinator ESMO Board of Directors & NR Committee Chair EORTC Breast Group Past-Chair
2 DISCLOSURES SLIDE Financial disclosures: Personal financial interest in form of consultancy role for: Amgen, Astellas/Medivation, AstraZeneca, Celgene, Daiichi-Sankyo, Eisai, GE Oncology, Genentech, GlaxoSmithKline, Macrogenics, Merck-Sharp, Merus BV, Mylan, Mundipharma, Novartis, Pfizer, Pierre-Fabre, Roche, Sanofi, Seattle Genetics, Teva. Institutional financial support for clinical trials from: Amgen, Astra-Zeneca, Boehringer-Ingelheim, Bristol-Myers-Squibb, Daiichi, Eisai, Fresenius GmbH, Genentech, GlaxoSmithKline, Ipsen, Incyte, Nektar Therapeutics, Nerviano, Novartis, Macrogenics, Medigene, MedImmune, Merck, Millenium, Pfizer, Pierre-Fabre, Roche, Sanofi-Aventis, Sonus, Tigris, Wilex, Wyeth. Non-Financial disclosures: Chair ABC Global Alliance and ABC Consensus Conference and Guidelines. Member/Committee Member of ESO, EORTC-BCG, IBCSG, SOLTI, ASCO, AACR, EACR, SIS, ASPIC
3 3 ISSUES TO DISCUSS: Fertility preservation Pregnancy after breast cancer Breast cancer during pregnancy
4 3 ISSUES TO DISCUSS: Fertility preservation Pregnancy after breast cancer Breast cancer during pregnancy
5 FERTILITY PRESERVATION All young women should be counseled about the risks and associated symptoms and outcomes of treatment-related amenorrhea and premature menopause before the onset of systemic therapy (either CT or ET) and referred for special counseling/consultation if interested in fertility preservation. TAKE HOME MESSAGE Do not forget to discuss fertility issues BEFORE starting the planned treatment
6 Pregnancy rate after cancer: not all alike Thyroid cancer Melanoma Non-Hodgkin's lymphoma Hodgkin's lymphoma All cancers Brain tumors Analysis adjusted for education level, previous pregnancy age Germ cell tumors Acute leukemia Cervical cancer Epithelial ovarian cancer Breast cancer % of young patients with breast cancer have a pregnancy Stensheim et al; Int J Cancer 2011 Courtesy F. Peccatori
7 TAKE HOME MESSAGES Inform the patient about the risk of infertility Refer her to the reproductive endocrinologist asap Consider egg/embryo freezing before chemotherapy Consider LHRHa during chemotherapy Offer participation in clinical trials Consider adapting CT regimens Adapted from F. Peccatori
8 Neo/adjuvant systemic treatment No age-specific neo/adjuvant CT regimen regarding efficacy and longterm tolerance is currently known. As for all stage I-III breast cancer patients, the preferred regimens are standard anthracycline, alkylating, and taxane based regimens. It is however possible to SPARE ALKYLATING AGENTS in many cases (specially non-tnbc)
9 Neoadjuvant systemic treatment In patients with TNBC or BRCA-associated tumors the incorporation of platinum agents increases pcr rates and may be considered when neoadjuvant chemotherapy is indicated. Data on the impact of incremental increases in pcr on long term outcome are not conclusive. (LoE: 2A) (77%) The use of platinum has potential additional impact on fertility and increased toxicity that may compromise standard duration and dosing of standard systemic treatment, and this needs to be clearly communicated to patients.
10 Consider LHRHa during chemo Lambertini et 2015, Annals of Oncology
11 Consider LHRHa during chemo Lambertini et 2015, Annals of Oncology
12 Pooled analysis of five randomized trials investigating temporary ovarian suppression with gonadotropinreleasing hormone analogs during chemotherapy as a strategy to preserve ovarian function and fertility in premenopausal early breast cancer patients Matteo Lambertini 1, Halle C.F. Moore 2, Robert C.F. Leonard 3, Sibylle Loibl 4, Pamela Munster 5, Marco Bruzzone 6, Luca Boni 7, Joseph M. Unger 8, Richard A. Anderson 9, Keyur Mehta 4, Susan Minton 10, Francesca Poggio 6, Kathy S. Albain 11, Douglas J.A. Adamson 12, Bernd Gerber 13, Amy Cripps 14, Gianfilippo Bertelli 15, Sabine Seiler 4, Marcello Ceppi 6, Ann H. Partridge 16, and Lucia Del Mastro 6 Abstract GS4-01 Presented at San Antonio Breast Cancer Symposium, December 5-9, Slides are used with the permission of Dr Matteo Lambertini
13 Definition of premature ovarian insufficiency (POI) PROMISE- GIM6 1,2 No resumption of menstrual activity and postmenopausal levels of FSH and E2 POEMS/SWOG Moffitt-led trial 4 GBG-37 ZORO 5 Anglo Celtic S Group OPTION 6 Amenorrhea for the prior 6 months and postmenopausal levels of FSH No maintenance of menses and no resumption of menses No reappearance of two consecutive menstrual periods within 21 to 35 days Amenorrhea with elevated FSH Timing of POI after chemotherapy 12 months 24 months 24 months 6 months Between 12 and 24 months Sample size ER status for eligibility Upper age limit for eligibility ER-positive and ER-negative ER-negative only ER-positive and ER-negative ER-negative only ER-positive and ER-negative 45 years 49 years 44 years 45 years None Type of GnRHa Triptorelin Goserelin Triptorelin Goserelin Goserelin Del Mastro L et al, JAMA 2011;306: Lambertini M et al, JAMA 2015;314: Moore HCF et al, N Engl J Med 2015;372: Munster P et al, J Clin Oncol 2012;30: Gerber B et al, J Clin Oncol 2011;29: Leonard RCF et al, Ann Oncol 2017;28:
14 Premature-Ovarian Insufficiency Rate 50% 40% OR* 0.38 (95% CI ) P< % 30.9% Meta-analysis approach 30% 20% 10% 0% GnRHa Group n = 363 Control Group n = 359 *Odds ratio (OR) adjusted for age, estrogen receptor status, type and duration of chemotherapy administered Lambertini M, et al. Cancer Res. 2018;78(4 Suppl): Abstract GS4-01.
15 Post-Treatment Pregnancy Rate GnRHa Group: 37/359 (10.3%) vs Control Group: 20/367 (5.5%) Meta-analysis approach IRR* 1.83 (95% CI ) P =.030 Age distribution, years Estrogen receptor status Positive Negative GnRHa Group n = 37 Number (%) 37 (100) 0 (0.0) 6 (16.2) 31 (83.8) Control Group n = 20 Number (%) 20 (100) 0 (0.0) 2 (10.0) 18 (90.0) IRR, Incidence rate ratio Lambertini M, et al. Cancer Res. 2018;78(4 Suppl): Abstract GS4-01.
16 Disease-Free Survival/Overall Survival Median follow-up = 5.0 years (IQR, years) Disease-Free Survival, % HR* 1.01 (95% CI ) P =.999 Overall Survival, % HR* 0.67 (95% CI ) P =.083 Time Since Random Assignment, Years Time Since Random Assignment, Years *Hazard ratio adjusted for age, estrogen receptor status, type and duration of chemotherapy administered and tumor stage IQR, interquartile range Lambertini M, et al. Cancer Res. 2018;78(4 Suppl): Abstract GS4-01.
17 3 ISSUES TO DISCUSS: Fertility preservation Pregnancy after breast cancer Breast cancer during pregnancy
18 TAKE HOME MESSAGE IS PREGNANCY AFTER BREAST CANCER SAFE? YES Same risk of recurrence and death Even in hormone-dependent tumors
19 Pregnancy after Breast Cancer Meta-analysis Differences in DFS between the pregnant group and matched non-pregnant group Healthy mother effect Azim H A et al. JCO 2013;31:73-79
20 SUPPORTIVE CARE PREGNANCY AFTER BREAST CANCER Pregnancy after breast cancer should not be discouraged even in patients with HR positive disease, although all available data have limitations. Prospective data from a global clinical trial are being collected (POSITIVE Trial).
21 Screening/eligibility: Patients with ER+ early breast cancer 18 and 42 years at enrollment Completing months of ET (SERMs alone, GnRH analogue + SERM or AIs) 1 Stop ET 2 E N R O L L M E N T 3 months wash out POSITIVE STUDY The Baby Trial Up to 2 years break to allow conception, delivery ± breast feeding ET resumption to complete 5 (-10) yrs Follow-up Pregnancy desire 1 + CT 2 No more than 1 month prior enroll mos 10 yrs Ovarian function evaluation Translational research Uterine evaluation Circulating tumor DNA (ctdna) Genomic evaluation of primary breast tumor Psycho-oncology companion psychological distress, fertility concerns, decisional conflict
22 Open questions PREGNANCY AFTER BREAST CANCER What is the ideal interval between ET interruption and pregnancy? When is it considered safe to interrupt ET? What is the impact of different ETs in fertility? Tamoxifen, Aromatase Inhibitor Ovarian Function Suppression
23 ADVANCED BREAST CANCER (ABC) (i.e. metastatic disease diagnosed before the age of 40) Is pregnancy always out of the question in advanced breast cancer?
24 3 ISSUES TO DISCUSS: Fertility preservation Pregnancy after breast cancer Breast cancer during pregnancy
25 BREAST CANCER DIAGNOSED DURING PREGNANCY Epidemiology - 1/100 cancers in reproductive age are diagnosed during pregnancy - 1/1000 pregnancies are complicated with cancer de Haan J et al, Lancet Oncol 2018 Courtesy F. Peccatori
26 EPIDEMIOLOGY 1/3.000 pregnancies, 5-10% breast cancer < 40 y/o Berry DL et al, JCO 1999 Courtesy F. Peccatori
27 Possible causes: Increasing age at pregnancy Courtesy F. Peccatori
28 Possible causes: Increasing incidence of breast cancer in young women Courtesy F. Peccatori
29 Matching variables (1 case: 2 controls) Age (±2 years) Year of surgery (±2 years) pt (1a vs. 1b vs. 1c vs. 2 vs. 3 vs. X) # of positive nodes (0 vs. 1-3 vs. 4-9 vs. 10+) Neoadjuvant chemotherapy (Yes vs. No) Azim HA Jr et al; Acta Oncol 2012
30 Clinical characteristics Age (years) Year of Surgery pt pn < Pregnant Cases N = (30.8) 33 (50.8) 12 (18.5) Controls N = (31.5) 61 (46.9) 28 (21.5) Median 36 (28-47) 36 (28-47) a-b 1c 2 3 X pn0 pn1 pn2 pn3 pnx 16 (24.6) 20 (30.8) 16 (24.6) 13 (20.0) 37 (28.5) 35 (26.9) 36 (27.7) 22 (16.9) Median (7.6) 21 (32.3) 31 (47.7) 6 (9.2) 2 (3.1) 28 (43.1) 19 (29.2) 10 (15.4) 6 (9.2) 2 (3.1) 10 (7.6) 42 (32.3) 62 (47.7) 12 (9.2) 4 (3.1) 56 (43.1) 38 (29.2) 20 (15.4) 12 (9.2) 4 (3.1) Azim HA Jr et al; Acta Oncol 2012 Courtesy F. Peccatori
31 Biological characteristics: no major differences Pregnant Cases N = 65 Controls N = = 130 p Estrogen Receptor Present Absent 43 (66.1) 22 (33.9) 98 (75.4) 32 (24.6) Progesteron Receptor Present Absent 42 (64.6) 23 (35.4) 87 (66.9) 43 (33.1) Grade (7.5) 18 (34.0) 31 (58.5) 4 (3.6) 43 (39.1) 63 (57.3) Ki-67 % < (28.6) 45 (71.4) 30 (23.4) 98 (76.6) Her2/neu Negative Positive 54 (83.1) 11 (16.9) 103 (81.1) 24 (18.9) Perivascular Invasion Absent Present 31 (47.7) 34 (52.3) 70 (55.1) 57 (44.9) Molecular subtypes Luminal A Luminal B Her2/Neu Triple Negative 8 (12.3) 37 (56.9) 6 (9.2) 14 (21.5) 13 (10.3) 82 (65.1) 4 (3.2) 27 (21.4) Azim HA Jr et al; Acta Oncol 2012 Courtesy F. Peccatori
32 Molecular subtypes (IHC): similar distribution Basal Luminal-A Luminal-B HER2 Chi-square: p=0.68 Azim HA Jr et al; Acta Oncol 2012 Courtesy F. Peccatori
33 TILS 50% Pregnant: 2/86 patients (2.3%) Non-pregnant: 11/116 (9.6%), p<0.001 Courtesy F. Peccatori
34 Managing Breast Cancer during Pregnancy TAKE HOME MESSAGE TREATMENT MUST BE PERFORMED IN A SPECIALISED CENTER BY AN EXPERIENT MULTIDISCIPLINARY TEAM!
35 BREAST CANCER DURING PREGNANCY FIRST QUESTION: TO CONTINUE OR TO STOP THE PREGNANCY? Only when diagnosis happens very early (first trimester) this hypothesis needs consideration However, this is always a parents decision (independently of the time of pregnancy) NO IMPACT ON PROGNOSIS
36 BREAST CANCER DURING PREGNANCY 1 st QUESTION: To Continue or To Stop the Pregnancy? INTERRUPTING THE PREGANCY DOESN T ADD ANY BENEFIT TO THE MOTHER Azim HA Jr et al; Acta Oncol 2012 TAKE HOME MESSAGE DO NOT advise the patient that she must terminate pregnancy!
37 BREAST CANCER DURING PREGNANCY If the decision is to continue pregnancy: TAKE HOME MESSAGE AVOID PREMATURE DELIVERY! TAKE HOME MESSAGE TREAT AS YOU WOULD IN A NON-PREGNANT CASE (only few exceptions: ET, anti-her2)
38 BREAST CANCER DURING PREGNANCY Which type of exams can you perform during pregnancy? Breast Chest Safe Ultrasound Mammogram X-rays, Low dose CT scan (first trimester) DW-MRI* Not safe MRI with gadolinium X-rays, CT scan (beyond first trimester) Abdomen Ultrasound /DW-MRI* CT scan Bone DW-MRI* Bone scan Brain DW-MRI* Whole body DW-MRI* PET scan * Without gadolinium Courtesy F. Peccatori Note: EVERYTHING THAT IS NOT INDISPENSIBLE, POSTPONE!
39
40 BREAST CANCER DURING PREGNANCY Which type of treatments are possible during pregnancy? SURGERY: YES CHEMOTHERAPY: YES RADIOTHERAPY: Yes, with protection but preferable after delivery Hormonal and biological treatments: NO
41 BREAST CANCER DURING PREGNANCY SURGERY Breast Conservative Surgery is possible and preferable. Identical indications as in non-pregnant women. Sentinel node biopsy is feasible but without using blue dye. Radioisotope dosing should be the minimum possible.
42 SURGERY No difference in the surgical approach of breast cancer during pregnancy, but: - careful anesthesiological evaluation - fetal monitoring, when appropriate Picture courtesy of Prof F Amant Courtesy F. Peccatori
43 Sentinel lymph node during pregnancy is safe Number 145 Age 35 (28 45) Technique -99m TC albumin nanocolloid only -Blue dye only -Combined -Unknown 96 (66%) 14 (10%) 15 (10%) 20 (14%) Successful mapping 144 (99%) Mean number of SLN 3.2 Positive SLN 43 (30%) Loco regional events at median FU: 48m Neonatal adverse events 11 (7%) (only 1 case of axillary recurrence) NONE Courtesy F. Peccatori
44 Breast reconstruction during pregnancy is safe
45 RADIOTHERAPY BREAST CANCER DURING PREGNANCY Usually contra-indicated Associated to serious adverse impact on the fetus Wait until after delivery (no problem with the needed time)
46 BREAST CANCER DURING PREGNANCY SYSTEMIC TREATMENTS: crucial importance of GESTACIONAL AGE 1st TRIMESTER Risk of malformations is 20% Cardonick E & Iacobucci; Lancet Oncol 2004
47 CHEMOTHERAPY DURING PREGNANCY The placenta Courtesy F. Peccatori
48 Maternal/fetal transfer of chemotherapy (apes) Number Drug detected in fetus (n) % drug detected in fetus Doxorubicin ± 3.2 Epirubicin ± 1.6 Paclitaxel ± 0.8 Docetaxel Cyclophosphamide ± 6.3 Carboplatin ± 14.2 DOXORUBICIN EPIRUBICIN Kristel van Calsteren et al; Gynecol Oncol 2011 Courtesy F. Peccatori
49 BREAST CANCER DURING PREGNANCY CHEMOTHERAPY RECOMMENDATIONS MDT team (including also obstetrics and neonatology) Treat as similar as possible to a non pregnant patient Prefer sequential CT (less toxic, identical efficacy) e.g. Epirubicin followed by weekly Paclitaxel Dosing according to real weight (not excluding the baby) Support measures (ex: antiemetics yes; growth factors no) Pregnancy Surveillance: Ultrasound after each cycle of CT
50 Chemotherapy effects on pregnancy and fetus Loibl et al; Lancet Oncol 2012
51 Chemotherapy effects on newborns Loibl et al; Lancet Oncol 2012
52 CHILD LONG TERM EFFECTS Lancet Oncol 2012; 13: Fetal exposure to chemotherapy was not associated with increased CNS morbidity.compared with the general population.
53 CHILD LONG TERM EFFECTS MAIN MESSAGE: AVOID PREMATURE DELIVERY! Long term cognitive function is related with date of delivery but not with the number of CT cycles Each additional pregnancy month is associated to a rise of 11.6 points in the Intelligence Coefficient Scale
54 Anthracycline (N=328), Taxanes (N=84), Platinum (N=74) No impact on short-term fetal mortality
55 Peccatori FA, Corrado G, Fumagalli M. Nat Rev Clin Oncol 2015
56 BREAST CANCER DURING PREGNANCY SYSTEMIC TREATMENT: HORMONAL THERAPY NO! HIGH RISK OF MALFORMATIONS! SYSTEMIC TREATMENT: TRASTUZUMAB NO! HIGH RISK OF MALFORMATIONS! (anidramnios) Specially in the 2nd e 3rd trimester (different from other drugs)
57 MOTHER PROGNOSIS (Young women!)
58 Prognosis (DFS & OS) DFS OS p-value: p-value: Pregnant cases (n=65) Controls (n=120) Median follow up: 51 months Azim HA Jr et al; Acta Oncol 2012 Courtesy F. Peccatori
59 NEED FOR MORE INFORMATION: EUROPEAN REGISTRIES Registry for breast cancer during pregnancy GBG-29 BIG www. germanbreastgroup.de/pregnancy With support of the BANSS-Foundation
60 BREAST CANCER DURING PREGNANCY: CONCLUSIONS Courtesy F. Peccatori
61
Dear doctor, what about a baby? Myths and facts
Dear doctor, what about a baby? Myths and facts OLIVIA PAGANI BREAST UNIT AND INSTITUTE OF ONCOLOGY OF SOUTHERN SWITZERLAND IBCSG Background About 15% of patients with BC are diagnosed during their reproductive
More informationLa preservazione della fertilità in oncologia: il carcinoma mammario come paradigma. Olivia Pagani Centro di Senologia dellasvizzera Italiana
La preservazione della fertilità in oncologia: il carcinoma mammario come paradigma Olivia Pagani Centro di Senologia dellasvizzera Italiana Centro di Senologia della Svizzera Italiana Pregnancy rate after
More information03/14/2019. GnRH Analogs for Fertility Preservation: What are the Data? Educational Objectives. Outline
GnRH Analogs for Fertility Preservation: What are the Data? AHN-JH SKCCC Current Topics in Breast Cancer Symposium Karen Lisa Smith MD MPH Assistant Professor Johns Hopkins Breast and Cancer Program March
More informatione-session 381 BCY3 - Highlights of the 3rd ESO-ESMO Breast Cancer in Young Women International Conference
Expert: Dr Olivia Pagani, Oncology Institute of Southern Switzerland, Lugano, Switzerland Discussant: Dr Fedro Alessandro Peccatori, European Institute of Oncology, Milan, Italy e-session 381 BCY3 - Highlights
More informationEARLY BREAST CANCER, HER2-POSITIVE
EARLY BREAST CANCER, HER2-POSITIVE CLINICAL CASE DISCUSSION Elżbieta Senkus Medical University of Gdańsk Gdańsk, Poland esmo.org DISCLOSURES Honoraria: Amgen, Astellas, AstraZeneca, Bayer, BMS, Celgene,
More informationBREAST JOURNAL CLUB LONG-TERM OUTCOME RESULTS OF THE PHASE III PROMISE- GIM6 STUDY EVALUATING THE ROLE OF LHRH ANALOG
BREAST JOURNAL CLUB LONG-TERM OUTCOME RESULTS OF THE PHASE III PROMISE- GIM6 STUDY EVALUATING THE ROLE OF LHRH ANALOG (LHRHa) DURING CHEMOTHERAPY AS A STRATEGY TO REDUCE OVARIAN FAILURE IN EARLY BREAST
More informationUpdates From San Antonio Breast Cancer Symposium 2017
Updates From San Antonio Breast Cancer Symposium 2017 Rob Coleman University of Sheffield Presentation Outline New Insights into adjuvant endocrine treatment Duration of treatment Perioperative therapy
More informationBiology of Young Breast Cancer and Management in Pregnant Women
19 th BSMO Annual Meeting 2017 Breast Cancer Task Force Biology of Young Breast Cancer and Management in Pregnant Women Matteo Lambertini, MD ESMO Fellow Institut Jules Bordet, Brussels Diegem, Belgium
More informationPoint of View on Early Triple Negative
Point of View on Early Triple Negative Valentina Rossi, MD UOSD Oncologia dei Tumori della Mammella Azienda Ospedaliera S.Camillo-Forlanini VRossi@scamilloforlanini.rm.it Outline Neoadjuvant Setting IPSY-2
More informationOnco-fertility. Fertility issues in young women with breast cancer in Japan. National Cancer Center Hospital, Tokyo Chikako Shimizu, MD
Onco-fertility Fertility issues in young women with breast cancer in Japan National Cancer Center Hospital, Tokyo Chikako Shimizu, MD COI disclosure Chikako Shimizu receives contracted research fund from
More informationESMO Breast Cancer Preceptorship Singapore November Special Issues in Treatment of Young Women with Breast Cancer
ESMO Breast Cancer Preceptorship Singapore November 2017 Special Issues in Treatment of Young Women with Breast Cancer Prudence Francis MD Peter MacCallum Cancer Centre Melbourne, Australia Conflict of
More informationDr. Matteo Lambertini
CONGRESSO NAZIONALE AIOM GIOVANI SESSIONE: PREMIAZIONE MIGLIORI TRE LAVORI GIOVANI SOPPRESSIONE OVARICA CON LHRH ANALOGHI DURANTE CHEMIOTERAPIA PER LA PRESERVAZIONE DELLA FUNZIONE OVARICA E DELLA FERTILITÀ
More informationPregnancy and Breast Cancer. Elena Provenzano Addenbrookes Hospital Cambridge
Pregnancy and Breast Cancer Elena Provenzano Addenbrookes Hospital Cambridge Pregnancy and Breast Cancer Pregnancy and Breast Cancer 1. Pregnancy associated breast cancer: Histology, management, clinical
More informationAdjuvant Endocrine Therapy in Premenopausal Patients
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Adjuvant Endocrine Therapy in Premenopausal Patients Adjuvant Endocrine Therapy in Premenopausal Patients www.agoonline.de
More informationA case of a BRCA2-mutated ER+/HER2 breast cancer during pregnancy
ESMO Preceptorship Programme Breast Cancer Lisbon 16,17 September 2016 Emanuela Risi Sandro Pitigliani Medical Oncology Department Hospital of Prato, Istituto Toscano Tumori, Prato, Italy A case of a BRCA2-mutated
More information38 years old, premenopausal, had L+snbx. Pathology: IDC Gr.II T-1.9cm N+2/4sn ER+100%st, PR+60%st, Her2-neg, KI %
38 years old, premenopausal, had L+snbx Pathology: IDC Gr.II T-1.9cm N+2/4sn ER+100%st, PR+60%st, Her2-neg, KI67 5-10% Question: What will you do now? 1. Give adjuvant chemotherapy 2. Send for Oncotype
More informationAdjuvant Systemic Therapy in Early Stage Breast Cancer
Adjuvant Systemic Therapy in Early Stage Breast Cancer Julie R. Gralow, M.D. Director, Breast Medical Oncology Jill Bennett Endowed Professor of Breast Cancer Professor, Global Health University of Washington
More informationBreast Cancer Breast Managed Clinical Network
Initial Evaluation Clinical Stage Pre-Treatment Evaluation Treatment and pathological stage Less than 4 positive lymph nodes Adjuvant Treatment ER Positive HER2 Negative (see page 2 & 3 ) HER2 Positive
More information(Neo-) adjuvant endocrine therapy
(Neo-) adjuvant endocrine therapy F. Cardoso, MD Director, Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal ESO Breast Cancer Program Coordinator ESMO Board of Directors & Chair NR Committee
More informationSystemic Therapy Considerations in Inflammatory Breast Cancer
Systemic Therapy Considerations in Inflammatory Breast Cancer Shani Paluch-Shimon, MBBS, MSc Director, Breast Oncology Unit Shaare Zedek Medical Centre, Jerusalem Israel Disclosures Roche: Speakers bureau,
More informationSan Antonio Breast Cancer Symposium, December 5-9, San Antonio Breast Cancer Symposium, December 5-9, 2017
San Antonio Breast Cancer Symposium, December 5-9, 2017 Survival analysis of the prospectively randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy with weekly nab-paclitaxel with solvent-based
More informationBreast cancer & Fertility. Do we provide good information?
Breast cancer & Fertility. Do we provide good information? M Fastrez, C Houba 27 4 13 CHU S t Pierre Réseau IRIS University of Brussels We have no conflict of interest to disclose. Summary Introduction:
More informationAny News in EBC? Ann H. Partridge, MD, MPH Dana-Farber Cancer Institute November 11, 2016
Any News in EBC? Ann H. Partridge, MD, MPH Dana-Farber Cancer Institute November 11, 2016 Yes! Age disparities vary by tumor subtype Genomic risk prediction data in young women Adjuvant systemic therapy
More informationClinical Management Guideline for Breast Cancer
Initial Evaluation Clinical Stage Pre-Treatment Evaluation Treatment and pathological stage Adjuvant Treatment Less than 4 positive lymph nodes ER Positive HER2 Negative (see page 2 & 3 ) Primary Diagnosis:
More informationAdjuvant Endocrine Therapy in Premenopausal Patients
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Adjuvant Endocrine Therapy in Premenopausal Patients Adjuvant Endocrine Therapy in Premenopausal Patients Version 2002: Scharl
More informationFollow-up Care of Breast Cancer Patients
Follow-up Care of Breast Cancer Patients Dr. Simon D. Baxter, MD, FRCPC Medical Oncologist BC Cancer Kelowna Clinical Instructor, Dept of Medicine University of British Columbia 19 April 2018 Disclosures
More informationUse of Ovarian Suppression and Ablation in Breast Cancer Treatment
Use of Ovarian Suppression and Ablation in Breast Cancer Treatment Dr Marina Parton Consultant Medical Oncologist Royal Marsden and Kingston Hospitals Overview Breast cancer phenotypes Use of ovarian manipulation
More informationUK Interdisciplinary Breast Cancer Symposium. Should lobular phenotype be considered when deciding treatment? Michael J Kerin
UK Interdisciplinary Breast Cancer Symposium Should lobular phenotype be considered when deciding treatment? Michael J Kerin Professor of Surgery National University of Ireland, Galway and Galway University
More informationNeoadjuvant (Primary) Systemic Therapy
Diagnosis and Treatment of Patients with Primary and Metastatic reast Cancer Neoadjuvant (Primary) Systemic Therapy Neoadjuvant Systemic Therapy Versions 2002 2017: auerfeind / lohmer / Costa / Dall /
More informationBreast Cancer Earlier Disease. Stefan Aebi Luzerner Kantonsspital
Breast Cancer Earlier Disease Stefan Aebi Luzerner Kantonsspital stefan.aebi@onkologie.ch Switzerland Breast Cancer Earlier Disease Diagnosis and Prognosis Local Therapy Surgery Radiation therapy Adjuvant
More informationBreast Cancer. Most common cancer among women in the US. 2nd leading cause of death in women. Mortality rates though have declined
Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women Mortality rates though have declined 1 in 8 women will develop breast cancer Breast Cancer Breast cancer increases
More informationCancer Survivorship: Meeting the Needs of a Growing Population
Cancer Survivorship: Meeting the Needs of a Growing Population Ann H. Partridge, MD, MPH 2018 Master Class Course Disclosure I have nothing to disclose. Off Label/Investigational Discussion In accordance
More informationBreast Cancer. Saima Saeed MD
Breast Cancer Saima Saeed MD Breast Cancer Most common cancer among women in the US 2nd leading cause of death in women 1 in 8 women will develop breast cancer Incidence/mortality rates have declined Breast
More informationSYSTEMIC TREATMENT OF TRIPLE NEGATIVE BREAST CANCER
SYSTEMIC TREATMENT OF TRIPLE NEGATIVE BREAST CANCER Sunil Shrestha 1*, Ji Yuan Yang, Li Shuang and Deepika Dhakal Clinical School of Medicine, Yangtze University, Jingzhou, Hubei Province, PR. China Department
More informationEmerging Approaches for (Neo)Adjuvant Therapy for ER+ Breast Cancer
Emerging Approaches for (Neo)Adjuvant Therapy for E+ Breast Cancer Cynthia X. Ma, M.D., Ph.D. Associate Professor of Medicine Washington University in St. Louis Outline Current status of adjuvant endocrine
More informationTriple Negative Breast cancer New treatment options arenowhere?
Triple Negative Breast cancer New treatment options arenowhere? Ofer Rotem, M.D., B.Sc. Breast Unit, Davidoff center Rabin Medical center October 2017 Case 6/2013 - M.D., 38 years old woman, healthy, no
More informationBreast Cancer. Dr. Andres Wiernik 2017
Breast Cancer Dr. Andres Wiernik 2017 Agenda: The Facts! (Epidemiology/Risk Factors) Biological Classification/Phenotypes of Breast Cancer Treatment approach Local Systemic Agenda: The Facts! (Epidemiology/Risk
More informationTriple Negative Breast Cancer: Part 2 A Medical Update
Triple Negative Breast Cancer: Part 2 A Medical Update April 29, 2015 Tiffany A. Traina, MD Breast Medicine Service Memorial Sloan Kettering Cancer Center Weill Cornell Medical College Overview What is
More informationCOME HOME Innovative Oncology Business Solutions, Inc.
Innovative Oncology Business Solutions, Inc. Breast Cancer Diagnostic/Therapeutic Pathway V11, April 2015 Required Structured Data Fields: ICD9 Code Stage Staging Components Performance Status Treatment
More informationLocally Advanced Breast Cancer: Systemic and Local Therapy
Locally Advanced Breast Cancer: Systemic and Local Therapy Joseph A. Sparano, MD Professor of Medicine & Women s Health Albert Einstein College of Medicine Associate Chairman, Department of Oncology Montefiore
More informationConsiderations in Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology
Considerations in Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology 80 70 60 50 40 30 20 10 0 EBCTCG 2005/6 Overview Control Arms with No Systemic Treatment
More informationNeoadjuvant Treatment of. of Radiotherapy
Neoadjuvant Treatment of Breast Cancer: Role of Radiotherapy Neoadjuvant Chemotherapy Many new questions for radiation oncology? lack of path stage to guide indications should treatment response affect
More informationEvolving Insights into Adjuvant Chemotherapy. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology
Evolving Insights into Adjuvant Chemotherapy Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology US Oncology 80 70 60 50 40 30 20 10 0 EBCTCG 2005/6 Overview Control Arms with No Systemic
More informationEndocrine Therapy in Premenopausal Breast Cancer. Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology, PA US Oncology
Endocrine Therapy in Premenopausal Breast Cancer Joyce O Shaughnessy, MD Baylor Sammons Cancer Center Texas Oncology, PA US Oncology Ovarian Ablation or Suppression vs. Not in ER + or ER UK Breast Cancer
More informationCáncer de mama HER2+/RE+ vs HER2+/RE : Una misma enfermedad? Dra E. Ciruelos Departamento de Oncología Médica Hospital Universitario 12 de Octubre
Cáncer de mama HER2+/RE+ vs HER2+/RE : Una misma enfermedad? Dra E. Ciruelos Departamento de Oncología Médica Hospital Universitario 12 de Octubre Recurrence of HER2-positive breast cancer (A) Time to
More information(Neo-) adjuvant endocrine therapy
(Neo-) adjuvant endocrine therapy F. Cardoso, MD Director, Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal ESO Breast Cancer Program Coordinator ESMO Board of Directors & NR Committee Chair
More informationThe Role of Pathologic Complete Response (pcr) as a Surrogate Marker for Outcomes in Breast Cancer: Where Are We Now?
1 The Role of Pathologic Complete Response (pcr) as a Surrogate Marker for Outcomes in Breast Cancer: Where Are We Now? Terry Mamounas, M.D., M.P.H., F.A.C.S. Medical Director, Comprehensive Breast Program
More informationOPTIMAL ENDOCRINE THERAPY IN EARLY BREAST CANCER
OPTIMAL ENDOCRINE THERAPY IN EARLY BREAST CANCER STEPHEN E. JONES, M.D. US ONCOLOGY RESEARCH THE WOODLANDS, TX TOPICS PREMENOPAUSAL BREAST CANCER POSTMENOPAUSAL BREAST CANCER THE FUTURE TOPICS PREMENOPAUSAL
More informationNEOADJUVANT THERAPY FOR BREAST CANCER: LOCAL EXPERT OPINION AND RECENT EVIDENCE
NEOADJUVANT THERAPY FOR BREAST CANCER: LOCAL EXPERT OPINION AND RECENT EVIDENCE Dr. Joanne Chiu Medical Oncology Queen Mary Hospital The University of Hong Kong HONG KONG SURVEY FOR NEOADJUVANT THERAPY
More informationFERTILITY AND PREGNANCY AFTER BREAST CANCER LISA KOLP, MD JOHNS HOPKINS SCHOOL OF MEDICINE OCTOBER 2013
FERTILITY AND PREGNANCY AFTER BREAST CANCER LISA KOLP, MD JOHNS HOPKINS SCHOOL OF MEDICINE OCTOBER 2013 SPECIAL THANKS TO DR. MINDY CHRISTIANSON INTRODUCTION About 6-7% of breast cancers are diagnosed
More informationRadiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy. Julia White MD Professor, Radiation Oncology
Radiotherapy Management of Breast Cancer Treated with Neoadjuvant Chemotherapy Julia White MD Professor, Radiation Oncology Agenda Efficacy of radiotherapy in the management of breast cancer in the Adjuvant
More informationClinical Research on PARP Inhibitors and Triple-Negative Breast Cancer (TNBC)
Clinical Research on PARP Inhibitors and Triple-Negative Breast Cancer (TNBC) Eric P Winer, MD Disclosures for Eric P Winer, MD No real or apparent conflicts of interest to disclose Key Topics: PARP and
More informationSession II: Academic Research in Breast Cancer: Challenges and Opportunities Robert L. Comis, MD ECOG-ACRIN Group Co-Chair
Session II: Academic Research in Breast Cancer: Challenges and Opportunities Robert L. Comis, MD ECOG-ACRIN Group Co-Chair Symposium: Innovation in Breast Cancer 2014 Madrid, Spain February 21, 2014 Cancer
More informationBreast cancer treatment
Report from the San Antonio Breast Cancer Symposium Breast cancer treatment Determining the best options for select patient groups Sara Soldera, MD, Resident; Nathaniel Bouganim, MD, FRCPC, Medical Oncologist;
More informationORMONOTERAPIA ADIUVANTE: QUALE LA DURATA OTTIMALE? MARIANTONIETTA COLOZZA
ORMONOTERAPIA ADIUVANTE: QUALE LA DURATA OTTIMALE? MARIANTONIETTA COLOZZA THE NATURAL HISTORY OF HORMONE RECEPTOR- POSITIVE BREAST CANCER IS VERY LONG Recurrence hazard rate 0.3 0.2 0.1 0 ER+ (n=2,257)
More informationEARLY STAGE BREAST CANCER ADJUVANT CHEMOTHERAPY. Dr. Carlos Garbino
EARLY STAGE BREAST CANCER ADJUVANT CHEMOTHERAPY Dr. Carlos Garbino EARLY BREAST CANCER ADJUVANT CHEMOTHERAPY SUSTANTIVE DIFFICULTIES FOR A WORLDWIDE APPLICABILITY DUE TO IMPORTANT INEQUALITIES + IN DIFFERENT
More informationESMO SUMMIT MIDDLE EAST 2018
ESMO SUMMIT MIDDLE EAST 2018 Breast Clinical Cases Presentation Hampig Raphael Kourie, MD, MSc, MBioethics Faculty of Medicine, Saint Joseph University of Beirut, Lebanon 6-7 April 2018, Dubai, UAE CONFLICT
More informationOncotype DX testing in node-positive disease
Should gene array assays be routinely used in node positive disease? Yes Christy A. Russell, MD University of Southern California Oncotype DX testing in node-positive disease 1 Validity of the Oncotype
More informationMaria João Cardoso, MD, PhD
Locally Advanced Breast Cancer Specific Issues in LocorregionalTreatment Surgery, MD, PhD Head Breast Surgeon Breast Unit, Champalimaud Foundation Lisbon, Portugal 1 Conflict of Interest Disclosure No
More informationPostoperative Adjuvant Chemotherapies. Stefan Aebi Luzerner Kantonsspital
Postoperative Adjuvant Chemotherapies Stefan Aebi Luzerner Kantonsspital stefan.aebi@onkologie.ch Does Chemotherapy Work in Older Patients? ER : Chemotherapy vs nil Age
More informationSOFTly: The Long Natural History of [Trials for] [premenopausal] ER+ Breast Cancer
SOFTly: The Long Natural History of [Trials for] [premenopausal] ER+ Breast Cancer Charles Moertel Lecture May 12, 2017 Gini Fleming Charles Moertel Founder of NCCTG Dedication to high quality clinical
More informationImpact of BMI on pathologic complete response (pcr) following neo adjuvant chemotherapy (NAC) for locally advanced breast cancer
Impact of BMI on pathologic complete response (pcr) following neo adjuvant chemotherapy (NAC) for locally advanced breast cancer Rachna Raman, MD, MS Fellow physician University of Iowa hospitals and clinics
More informationFollow-up Care of Breast Cancer Patients
Follow-up Care of Breast Cancer Patients Dr. Simon D. Baxter, MD, FRCPC Medical Oncologist BC Cancer Kelowna Clinical Instructor, Dept of Medicine University of British Columbia 24 November 2018 Disclosures
More informationThe Oncotype DX Assay in the Contemporary Management of Invasive Early-stage Breast Cancer
The Oncotype DX Assay in the Contemporary Management of Invasive Early-stage Breast Cancer Cancer The Biology Century Understanding and treating the underlying tumor biology Cancer genetic studies demonstrate
More information10/16/2014. Adolescents (ages 10 19) and young adults (ages 20 24) together compose about 21% of the population of the United States.
The purview of pediatrics includes the growth, development, and health of the child and therefore begins in the period before birth when conception is apparent. It continues through childhood and adolescence
More informationMdi Medical Management of Breast Cancer Morbidity and Mortality Aug 13, 2009 Irina Kovatch, PGY3 Introduction Metastatic disease is the principal cause of death from breast cancer Metastatic events often
More informationAdvances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings. Eve Rodler, MD University of California at Davis October 2016
Advances in Breast Cancer Therapeutics in the Adjuvant and Metastatic Settings Eve Rodler, MD University of California at Davis October 2016 17th Annual Advances in Oncology September 30-October 1, 2016
More informationThe Neoadjuvant Model as a Translational Tool for Drug and Biomarker Development in Breast Cancer
The Neoadjuvant Model as a Translational Tool for Drug and Biomarker Development in Breast Cancer Laura Spring, MD Breast Medical Oncology Massachusetts General Hospital Primary Mentor: Dr. Aditya Bardia
More informationBRCA mutation carrier patient: How to manage?
BRCA mutation carrier patient: How to manage? Clinical Case Presentation Katarzyna Sosińska-Mielcarek Department of Oncology and Radiotherapy University Clinical Center Gdansk, Poland esmo.org DISCLOSURE
More informationIntro to Cancer Therapeutics
An Intro to Cancer Therapeutics Christopher R. Chitambar, MD Professor of Medicine Division of Hematology & Oncology Froedtert and Medical College of Wisconsin Clinical Cancer Center cchitamb@mcw.edu Intro
More informationNon-Anthracycline Adjuvant Therapy: When to Use?
Northwestern University Feinberg School of Medicine Non-Anthracycline Adjuvant Therapy: When to Use? William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley Center for
More informationBreast cancer (screening) in older individuals: the oncologist s viewpoint for the geriatrician
Breast cancer (screening) in older individuals: the oncologist s viewpoint for the geriatrician Hans Wildiers Medical oncologist, Leuven, Belgium Past chairman of the EORTC elderly task force President-elect
More informationABC Global Alliance. F. Cardoso, MD
ABC Global Alliance F. Cardoso, MD Director, Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal ESO Breast Cancer Program Coordinator ESMO Board of Directors & NR Committee Chair EORTC Breast
More informationPMRT for N1 breast cancer :CONS. Won Park, M.D., Ph.D Department of Radiation Oncology Samsung Medical Center
PMRT for N1 breast cancer :CONS Won Park, M.D., Ph.D Department of Radiation Oncology Samsung Medical Center DBCG 82 b & c Overgaard et al Radiot Oncol 2007 1152 pln(+), 8 or more nodes removed Systemic
More informationBreast Cancer? Breast cancer is the most common. What s New in. Janet s Case
Focus on CME at The University of Calgary What s New in Breast Cancer? Theresa Trotter, MD, FRCPC Breast cancer is the most common malignancy affecting women in Canada, accounting for almost a third of
More informationTerapia Hormonal da Paciente Premenopausa
I Congresso de Oncologia D Or 5 e 6 de julho de 2013 Terapia Hormonal da Paciente Premenopausa Antonio C. Wolff, MD, FACP, FASCO Professor de Oncologia Programa de Câncer de Mama Johns Hopkins University
More informationNeoadjuvantTreatment In BC When, How, Who?
NeoadjuvantTreatment In BC When, How, Who? Clifford Hudis, M.D. Chief, Breast Cancer Medicine Service, MSKCC Professor of Medicine, Weill Cornell Medical College President, ASCO 15 Potential Benefits Of
More information10/15/2012. Inflammatory Breast Cancer vs. LABC: Different Biology yet Subtypes Exist
Triple-Negative Breast Cancer: Optimizing Treatment for Locally Advanced Breast Cancer Beth Overmoyer MD Director, Inflammatory Breast Cancer Program Dana Farber Cancer Institute Overview Inflammatory
More informationPredicting outcome in metastatic breast cancer
Predicting outcome in metastatic breast cancer Aleix Prat, MD, PhD Medical Oncology Department Translational Genomics and Targeted Therapeutics in Solid Tumors Monday, 15 th January, Manchester, UK Disclosures
More informationLong Term Toxicity of Endocrine Therapy for premenopausal women with ER positive breast cancer
Global Breast Cancer Conference 2017 21 st Apr, 2017@Chezu Island Long Term Toxicity of Endocrine Therapy for premenopausal women with ER positive breast cancer Shinji Ohno, M.D., Ph.D., F.A.C.S. Breast
More informationObjectives Critically review presentations on 1. Local therapy 2. Adjuvant chemotherapy for isolated local regional recurrence 3. The optimal duration
Objectives Critically review presentations on 1. Local therapy 2. Adjuvant chemotherapy for isolated local regional recurrence 3. The optimal duration of endocrine therapy 4. Advances in HER2 directed
More information8/8/2011. PONDERing the Need to TAILOR Adjuvant Chemotherapy in ER+ Node Positive Breast Cancer. Overview
Overview PONDERing the Need to TAILOR Adjuvant in ER+ Node Positive Breast Cancer Jennifer K. Litton, M.D. Assistant Professor The University of Texas M. D. Anderson Cancer Center Using multigene assay
More informationA Slow Starvation: Adjuvant Endocrine Therapy of Breast Cancer
A Slow Starvation: Adjuvant Endocrine Therapy of Breast Cancer Dr. Susan Ellard Surgical Oncology Update October 24, 2009 Disclosure slide Participant in various meetings or advisory boards sponsored by
More informationEarly Stage Disease. Hope S. Rugo, MD Professor of Medicine Director Breast Oncology and Clinical Trials Education UCSF Comprehensive Cancer Center
SABCS 2014: Early Stage Disease Hope S. Rugo, MD Professor of Medicine Director Breast Oncology and Clinical Trials Education UCSF Comprehensive Cancer Center Topics for Discussion Chemotherapy plus 10
More informationWilliam J. Gradishar MD
Northwestern University Feinberg School of Medicine Adjuvant Endocrine Therapy For Postmenopausal Women SOBO 2013 William J. Gradishar MD Betsy Bramsen Professor of Breast Oncology Director, Maggie Daley
More informationPregnancy in the middle of adjuvant treatment of Her2 positive breast cancer
ESMO Preceptorship Programme ESMO Preceptorship ADOLESCENTS & YOUNG ADULTS MALIGNANCIES Lugano, Switzerland 11-12 May 2018 Petra Vuković, University Hospital for Tumors, University Hospital Center Sestre
More informationTriple negative breast cancer -neoadjuvant and adjuvant systemic therapy
Triple negative breast cancer -neoadjuvant and adjuvant systemic therapy Sung-Bae Kim, MD, PhD Department of Oncology Asan Medical Center University of Ulsan College of Medicine Seoul, Korea DISCLOSURE
More informationIt is a malignancy originating from breast tissue
59 Breast cancer 1 It is a malignancy originating from breast tissue including both early stages which are potentially curable, and metastatic breast cancer (MBC) which is usually incurable. Most breast
More informationJohns Hopkins Clinical Update Webinar
Johns Hopkins Clinical Update Webinar Ben Ho Park, M.D., Ph.D. Department of Oncology Johns Hopkins University February 2015 This presentation is the intellectual property of the author/presenter. Contact
More informationNeoadjuvant therapy a new pathway to registration?
Neoadjuvant therapy a new pathway to registration? Graham Ross, FFPM Clinical Science Leader Roche Products Ltd Welwyn Garden City, UK (full time employee) Themes Neoadjuvant therapy Pathological Complete
More informationXII Michelangelo Foundation Seminar
XII Michelangelo Foundation Seminar The opportunity of the neoadjuvant approach L. Gianni, Milan, I XII Michelangelo Foundation Seminar Milano, October 12, 2012 The opportunity of the neoadjuvant approach
More informationINITIAL EVALUATION. Ductal carcinoma in situ 2 (DCIS) See Ductal Carcinoma In Situ Breast Cancer Non-Invasive Algorithm
Pregnancy and Breast Cancer Page of 5 INITIAL EVALUATION Palpable mass greater than 2 weeks History and physical Bilateral mammogram with fetal shielding/ultrasound of breast and nodal basins Core biopsy
More informationLuminal early breast cancer: (neo-) adjuvant endocrine therapy
CAMPUS GROSSHADERN CAMPUS INNENSTADT KLINIK UND POLIKLINIK FÜR FRAUENHEILKUNDE UND GEBURTSHILFE DIREKTOR: PROF. DR. MED. SVEN MAHNER Luminal early breast cancer: (neo-) adjuvant endocrine therapy Nadia
More informationBreast Cancer in Young Women News from the BCY3 Consensus Conference
Expert Discussion Breast Care 2016;11:432 435 DOI: 10.1159/000454873 Published online: December 13, 2016 Breast Cancer in Young Women News from the BCY3 Consensus Conference Chair: Shani Paluch-Shimon
More informationAdjuvant chemotherapy in older breast cancer patients: how to decide?
Adjuvant chemotherapy in older breast cancer patients: how to decide? H. Wildiers University Hospitals Leuven Belgium Wildiers H, Kunkler I, Lancet Oncol 2007 Biganzoli L, Wildiers H, Lancet Oncol. 2012
More informationFertility Preservation for Breast Cancer. Elizabeth S. Ginsburg MD Medical Director, ART Program Brigham & Women s Hospital
Fertility Preservation for Breast Cancer Elizabeth S. Ginsburg MD Medical Director, ART Program Brigham & Women s Hospital Learning Objectives To be able to list and describe processes of ovulation induction
More informationImplications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers
日大医誌 75 (1): 10 15 (2016) 10 Original Article Implications of Progesterone Receptor Status for the Biology and Prognosis of Breast Cancers Naotaka Uchida 1), Yasuki Matsui 1), Takeshi Notsu 1) and Manabu
More informationSYSTEMIC THERAPY OPTIONS FOR BREAST CANCER IN 2014
SYSTEMIC THERAPY OPTIONS FOR BREAST Oncology Day 2014 CANCER IN 2014 Dr. Katherine Enright, M.D., M.P.H., F.R.C.P.(C) Katherine.enright@Trilliumhealthpartners.ca OBJECTIVES 1. Outline an approach to the
More informationBreast Cancer Basics. Clinical Oncology for Public Health Professionals. Ben Ho Park, MD, PhD
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this
More informationExtended Hormonal Therapy
Extended Hormonal Therapy Dr. Caroline Lohrisch, Medical Oncologist, BC Cancer Agency Vancouver Centre November 1, 2014 www.fpon.ca Optimal Endocrine Therapy for Women with Hormone Receptor Positive Early
More information